JERUSALEM--(BUSINESS WIRE)--BioLineRx (TASE:BLRX), a biopharmaceutical drug development company, today announced that it plans to list its shares through American Depositary Receipts (ADRs), to be traded on the NASDAQ under ticker “BLRX.” The Bank of New York Mellon has been appointed as the Company's depositary bank. “We believe that the ADR program is the best way to initially expand our reach to investors in the United States,” stated Dr. Kinneret Savitsky, BioLineRx's CEO. “We look forward to being able to offer US investors the opportunity to invest in BioLineRx through a premier, cutting-edge exchange like the NASDAQ.”
